Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda To Hunt For New CNS Therapeutics With Heptares' Technology

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical Company, which has targeted new central nervous system drugs as a core therapeutic research area, entered into a $100 million research collaboration April 11 with the U.K. biotech, Heptares Therapeutics Ltd., to characterize a G-protein coupled receptor (GPCR) believed to play a role in CNS disorders

You may also be interested in...



$400m Heptares Acquisition To Drive Sosei’s R&D

Sosei is to pay up to $400 million to acquire the UK structure-based drug design specialist Heptares Therapeutics in a move that the Japanese firm hopes will bring fresh fuel to its R&D engine, complementing its existing nanotech and peptide technologies.

Deals Of The Week: Shire/Heptares, NicOx/Altacor, UCB/Oxford University

This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.

Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains

TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC077638

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel